Clinical Trial: Phase III Study of RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy as First-Line Treatment for sqNSCLC

U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07416474) titled 'Phase III Study of RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy as First-Line Treatment for sqNSCLC' on Feb. 10.

Brief Summary: This study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous NSCLC who have not received first-line treatment. Participants will: Take RC148 or Tislelizumab combined with platinum-based chemotherapy until the end of the research.

Study Start Date: March 31

Study Type: INTERVENTIONAL

Condition: Non-S...